Loading
SEM1 (26S proteasome complex subunit SEM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.86, affected pathway 0.87, genetic association 0.05, clinical 0.99).
In plain words · SEM1 (26S proteasome complex subunit SEM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
SEM1 (26S proteasome complex subunit SEM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
No product in this corpus aims at SEM1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists SEM1 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA SEM1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining renal cancer (3 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SEM1 tissue; Open Targets ENSG00000127922 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Crackower M.A. et al, Hum. Mol. Genet, 1996, "Characterization of the split hand/split foot malformation locus SHFM1 at 7q21.3-q22.1 and analysis of a candidate gene for its expression during limb development". Source.
Sources: HGNC HGNC:10845 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P60896 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000127922 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Component of the TREX-2 complex (transcription and export complex 2), composed of at least ENY2, GANP, PCID2, SEM1, and either centrin CETN2 or CETN3. The TREX-2 complex functions in docking export-competent ribonucleoprotein particles (mRNPs) to the nuclear entrance of the nuclear pore complex (nuclear basket). TREX-2 participates in mRNA export and accurate chromatin positioning in the nucleus by tethering genes to the nuclear periphery. Location: Nucleus (UniProt). Locus 7q21.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: cervical cancer, glioma, head and neck cancer, lymphoma.
HPA SEM1 tissue · HPA SEM1 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SEM1" OR ABSTRACT:"SEM1" OR TITLE:"SEM1 26S proteasome subunit" OR ABSTRACT:"SEM1 26S proteasome subunit" OR TITLE:"26S proteasome complex subunit SEM1" OR ABSTRACT:"26S proteasome complex subunit SEM1" OR TITLE:"DSS1" OR ABSTRACT:"DSS1" OR TITLE:"Shfdg1" OR ABSTRACT:"Shfdg1" OR TITLE:"SHSF1" OR ABSTRACT:"SHSF1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SEM1, not a curated reading list.